Skip to main content
×
×
Home

The Role of Serotonin in Autism-Spectrum Disorders

  • Marc N. Potenza and Christopher J. Mcdougle
Abstract

While the etiologies of pervasive developmental disorders (PDDs) appear complicated, multifactorial, and relatively poorly understood research over the last 30 to 40 years has implicated certain neurochemicals in the pathophysiology of these diseases. From these studies, a great deal of evidence has emerged supporting a role for serotonergic dysfunction in individuals with autism and related disorders. Recent clinical trials of drugs influencing serotonergic systems have demonstrated promising effects in children, adolescents, and adults with PDDs.

Copyright
References
Hide All
1.American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994:65-78,417423.
2.Kaplan, HI, Sadock, BJ, Grebb, JF. Kaplan and Sadock's Synopsis of Psychiatry. 7th ed. Philadelphia, Pa: William & Wilkins; 1994:10521062.
3.Rapin, I. Introduction and overview. In: Bauman, ML, Kemper, TL, eds. The Neurobiology of Autism. Baltimore, Md: The Johns Hopkins University Press; 1994:117.
4.McDougle, CJ, Kresch, LE, Goodman, WK, et al.A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry. 1995;152:772777.
5.Lotter, V. Follow-up studies. In: Rutter, M, Schopler, E, eds. Autism: A Reappraisal of Concepts And Treatment. New York, NY: Plenum Press; 1978.
6.Gillberg, C. Outcome in autism and autistic-like conditions. J Am Acad Child Adolesc Psychiatry. 1991;30:375382.
7.Gillberg, C, Coleman, M. The Biology of the Autistic Syndromes. 2nd ed. London: MacKeith Press; 1992.
8.Bauman, ML, Kemper, TL. The Neurobiology of Autism. Baltimore, Md: Johns Hopkins University Press; 1994.
9.McDougle, CJ, Price, LH, Volkmar, FR. Recent advances in the pharmacotherapy of autism and related conditions. In: Volkmar, FR, ed. Psychoses and Pervasive Developmental Disorders. Philadelphia, Pa: W.B. Saunders; 1994:7189.
10.Volkmar, F, Klin, A, Marans, W, McDougle, CJ. Autistic disorder. In: Volkmar, F, ed. Psychoses and Pervasive Developmental Disorders in Childhood and Adolescence. Washington, DC: American Psychiatric Press; 1996:129190.
11.Rubenstein, JLR, Lotspeich, L, Ciaranello, RD. The neurobiology of developmental disorders. In: Lahey, BB, Kazdin, AE, eds. Advances in Clinical Child Psychology. New York, NY: Plenum Publishing Corporation; 1990; 13:152.
12.Gillberg, C, Svennerholm, L, Hamilton-Hellberg, C. Childhood psychosis and monoamine metabolites in spinal fluid. J Autism Dev Disord. 1983;13:383396.
13.Campbell, M, Anderson, LT, Meier, M, et al.A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry. 1978:17:640655.
14.Cohen, IL, Campbell, M, Posner, D, Small, AM, Triebel, D, Anderson, LT. Behavioral effects of haloperidol in young autistic children. J Am Acad Child Adolesc Psychiatry. 1980;19:665677.
15.Anderson, LT, Campbell, M, Grega, DM, Perry, R, Small, AM, Green, WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry. 1984; 141:11951202.
16.Anderson, L, Campbell, M. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989:19:227239.
17.Naruse, H, Nagahata, M, Nakane, Y, Shirahashi, K, Takesada, M, Yamazaki, K. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavior disorders, using cross-over design. Acta Paedopsychiatrica. 1982:48:173184.
18.Schain, RJ, Freedman, DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr. 1961:58:315320.
19.Anderson, GM. Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder. Medical Biology. 1987:65:6774.
20.Narayan, M, Srinath, S, Anderson, GM, Meundi, DB. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry. 1993:33:630635.
21.Kuperman, S, Beeghly, JH, Burns, TL, Tsai, LY. Serotonin relationships of autistic probands and their first-degree relatives. J Am Acad Child Adolesc Psychiatry. 1985:24:186190.
22.Abramson, RK, Wright, HH, Carpenter, R, et al.Elevated blood serotonin in autistic probands and their first-degree relatives. J Autism Dev Disord. 1989:19:397407.
23. Cook, E.H.Autism: review of neurochemical investigation. Synapse. 1990:6:292308.
24.Leventhal, BL, Cook, EH, Morford, M, Ravitz, A, Freedman, DX. Relationships of whole blood serotonin and norepinephrine within families. J Autism Dev Disord. 1990:20:499511.
25.Piven, J, Tsai, GC, Nehme, E, Coyle, JT, Chase, GA, Folstein, SE. Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord. 1991:21:5159.
26.Perry, BD, Cook, EH Jr, Leventhal, BL, Wainwright, MS, Freedman, DX. Platelet 5-HT2 serotonin receptor binding sites in autistic children and their first-degree relatives. Biol Psychiatry. 1991:30:121130.
27.Hanley, HG, Stahl, SM, Freedman, DX. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry. 1977:34:521531.
28.Kuperman, S, Beeghly, J, Burns, T, Tsai, L. Association of serotonin concentration to behavior and IQ in autistic children. J Autism Dev Disord. 1987:17:133140.
29.Todd, RD, Ciaranello, RD. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci U S A. 1985:82:612616.
30.Hoshino, Y, Yamamoto, T, Kaneko, M, et al.Blood serotonin and free tryptophan concentration in autistic children. Neuropsychobiology. 1984; 11:2227.
31.McBride, PA, Anderson, GM, Hertzig, ME, et al.Serotonergic responsivity in male young adults with autistic disorder. Results of a pilot study. Arch Gen Psychiatry. 1989;46:213221.
32.Rose, WC, Haines, WJ, Warner, DT. The amino acid requirements of man. J Biol Chem. 1954:206:421430.
33.Gal, EM, Dreses, PA. Studies on the metabolism of 5-hydrox-ytryptamine (serotonin), II: effect of tryptophan deficiency in rats. Proc Soc Exp Biol Med. 1962:110:368371.
34.Fernstrom, JD. Effects of the diet on brain neurotransmitters. Metabolism. 1977:26:207223.
35.Curzon, G. Influence of plasma tryptophan on brain 5HT synthesis and serotonergic activity. In: Haber, G, Gabay, S, eds. Serotonin: Current Aspects of Neurochemistry and Function. New York, NY: Plenum Press; 1981:207219.
36.Young, SN, Ervin, FR, Phil, RO, Finn, P. Biochemical aspects of tryptophan depletion in primates. Psychopharmacology (Berl). 1989:95:508511.
37.Moja, EA, Cipollo, P, Castoldi, D, Tofanetti, O. Dose-response decrease in plasma tryptophan and in brain tryptophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sci. 1989:44:971976.
38.Moir, ATB, Eccleston, D. The effects of precursor loading in the cerebral metabolism of 5-hydroxyindoles. J Neurochem. 1968:15:10931108.
39.Fernstrom, JD, Hirsch, MJ. Rapid repletion of brain serotonin in malnourished corn-fed rats following L-tryptophan injection. Life Sci. 1975:17:455464.
40.Delgado, PL, Charney, DS, Price, LH, Aghajanian, GK, Landis, H, Heninger, GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990:47:411418.
41.Barr, LC, Goodman, WK, McDougle, CJ, et al.Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994:51:309317.
42.Delgado, PL, Price, LH, Miller, HL, et al.Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry. 1994:51:865874.
43.Barr, LC, Goodman, WK, Delgado, PL, McDougle, CJ, Price, LH. Effects of tryptophan depletion in drug-free obsessive compulsive disorder patients. Biol Psychiatry. In press.
44.Goddard, AW, Sholomskas, DE, Augeri, FM, et al.Effects of tryptophan depletion in panic disorder. Biol Psychiatry. 1994:36:775777.
45.Young, SN, Smith, SE, Pihl, RD, Ervin, FR. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl). 1985:87:173177.
46.Smith, SE, Pihl, RO, Young, SWErvin, FR. A test of possible cognitive and environmental influences on the mood lowering effect of tryptophan depletion in normal males. Psychopharmacology. 1987:91:451457.
47.McDougle, CJ, Naylor, ST, Goodman, WK, Volkmar, FR, Cohen, DJ, Price, LH. Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry. 1993:33:547550.
48.McDougle, CJ, Naylor, ST, Cohen, CJ, Aghajanian, GK, Heninger, GR, Price, LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996:53:9931000.
49.Schuster, CR, Lewis, M, Seiden, LS. Fenfluramine: neurotoxicity. Psychopharmacol Bull. 1986:22:148151.
50.Geller, E, Ritvo, ER, Freeman, BJ, Yuwiler, A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med. 1982:307:165169.
51.Ritvo, ER, Freeman, BJ, Geller, E, Yuwiler, A. Effects of fenfluramine on 14 outpatients with the syndrome of autism. J Am Acad Child Adolesc Psychiatry. 1983:22:549558.
52.Ritvo, ER, Freeman, BJ, Yuwiler, A, et al.Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull. 1986:22:133140.
53.Stubbs, EG, Budden, SS, Jackson, RH, Terdal, LG, Ritvo, ER. Effects of fenfluramine on eight outpatients with the syndrome of autism. Dev Med Child Neurol. 1986:28:229235.
54.Stern, LM, Walker, MK, Sawyer, MG, Oades, RD, Badcock, NR, Spence, JG. A controlled crossover trial of fenfluramine in autism. J Child Psychol Psychiatry. 1990:31:569585.
55.Campbell, M, Perry, R, Small, AM, Green, WH. Overview of drug treatment in autism. In: Schopler, E, Mesibov, GB, eds. Neurobiological Issues in Autism. New York, NY: Plenum Press; 1987.
56.Ekman, G, Miranda-Linné, F, Gillberg, C, Garle, M, Wetterberg, L. Fenfluramine treatment of twenty children with autism. J Autism Dev Disord. 1989;19:511532.
57.Sherman, J, Factor, DC, Swinson, R, Darjes, RW. The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord. 1989:19:533543.
58.Duker, PC, Welles, K, Seys, D, Rensen, H, Vis, A. Brief report: effects of fenfluramine on communicative, stereotypic, and inappropriate behaviors of autistic-type mentally handicapped individuals. J Autism Dev Disord. 1991:21:355363.
59.Campbell, M, Fish, B, Shapiro, T, Floyd, AK Jr., Imipramine in preschool autistic and schizophrenic children. Journal of Autism and Childhood Schizophrenia. 1971; 1:267282.
60.Fish, B, Campbell, M, Shapiro, T, Floyd, A Jr., Schizophrenic children treated with methysergide (Sansert). Dis Nerv Syst. 1969; 30:534540.
61.Blier, P, de Montigny, C, Chaput, Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry. 1990:51 (suppl):1420.
62.Realmuto, GM, August, GJ, Garfinkel, BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989:9:122125.
63.Ratey, JJ, Sovner, R, Mikkelsen, E, Chmielinski, HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry. 1989:50:382384.
64.Gedye, A. Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult. Biol Psychiatry. 1991:30:8891.
65.Ricketts, RW, Goza, AB, Ellis, CR, et al.Clinical effects of buspirone on intractable self-injury in adults with mental retardation. J Am Acad Child Adolesc Psychiatry. 1994:33:270276.
66.Gedye, A. Serotonergic treatment for aggression in a Down's syndrome adult showing signs of Alzheimer's disease. Journal of Mental Deficiency Research. 1991:35:247258.
67.O'Neill, M, Page, N, Adkins, W. Tryptophan-trazodone treatment of aggressive behavior. Lancet. 1986:2:859860.
68.McDougle, CJ, Price, LH, Volkmar, FR, et al.Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992:31:746750.
69.Garber, HJ, McGonigle, JJ, Slomka, GT, Monteverde, E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry. 1992:31:11571160.
70.Gordon, CT, Rapoport, JL, Hamburger, SD, State, RC, Mannheim, GB. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry. 1992:149:363366.
71.Gordon, CT, State, RC, Nelson, JE, Hamburger, SD, Rapoport, JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993:50:441447.
72.Brodkin, ES, McDougle, CJ, Naylor, ST, Cohen, DJ, Price, LH. Clomipramine in adults with pervasive developmental disorders: A prospective, open-label investigation. Journal of Child and Adolescent Psychopharmocology. In press.
73.Brasic, JR, Barnett, JY, Kaplan, D, et al.Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 1994:44:13091312.
74.Sanchez, LE, Campbell, M, Small, AM, Cueva, JE, Armenteros, JL, Adams, PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry. 1996:35:537544.
75.Buck, OD. Sertraline for reduction of violent behavior. Am J Psychiatry. 1995:152:953.
76.Hellings, JA, Kelley, LA, Gabrielli, WF, Kilgore, E, Shah, P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996:53:333336.
77.Cook, EH Jr, Rowlett, R, Jaselskis, C, Leventhal, BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992:31:739745.
78.Mehlinger, R, Scheftner, WA, Poznanski, E. Fluoxetine and autism. J Am Acad Child Adolesc Psychiatry. 1990:29:985. Letter.
79.Hamdan-Allen, G. Brief report: trichotillomania in an autistic male. J Autism Dev Disord. 1991:21:7982.
80.Todd, RD. Fluoxetine in autism. Am J Psychiatry. 1991:148:1089. Letter.
81.Ghaziuddin, M, Tsai, L, Ghaziuddin, N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry. 1991:30:508509. Letter.
82.Ghaziuddin, M, Tsai, L. Depression in autistic disorder. Br J Psychiatry. 1991:159:721723.
83.Koshes, RJ. Use of fluoxetine for obsessive-compulsive behavior in adults with autism. Am J Psychiatry. 1997:154:578.
84.Snead, RW, Boon, F, Presberg, J. Paroxetine for self-injurious behavior. J Am Acad Child Adolesc Psychiatry. 1994:33:909910. Letter.
85.McDougle, CJ, Price, LH, Goodman, WK. Fluvoxamine treatment of coincident autistic disorder and obsessive compulsive disorder: a case report. J Autism Dev Disord. 1990:20:537543.
86.McDougle, CJ, Naylor, ST, Cohen, DJ, Volkmar, FR, Heninger, GR, Price, LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996:53:10011008.
87.Goodman, WK, Price, LH, Rasmussen, SA, et al.The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): part I. Development, use, and reliability. Arch Gen Psychiatry. 1989:46:10061011.
88.Goodman, WK, Price, LH, Rasmussen, SA, et al.The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): part II. Validity. Arch Gen Psychiatry. 1989:46:10121016.
89.Meltzer, HY. Atypical antipsychotic drugs. In: Bloom, FE, Kupfer, DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:12771286.
90.Potenza, MN, McDougle, CJ. Potential of “atypical” antipsychotics in the treatment of non-psychotic disorders. CNS Drugs. In press.
91.Zuddas, A, Ledda, MG, Fratta, A, Muglia, P, Cianchetti, C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry. 1996:153:738. Letter.
92.Borison, RL, Pathiraja, AP, Diamond, BL, Meibach, RC. Risperidone clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992:28:213218.
93.Owens, DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry. 1994:55:2935.
94.Purdon, SE, Lit, WLabelle, A, Jones, BD. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry. 1994:39:400405.
95.McDougle, CJ, Brodkin, ES, Yeung, PP, Naylor, ST, Cohen, DJ, Price, LH. Risperidone in adults with autism or pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology. 1995:5:273282.
96.Simeon, JG, Carrey, NJ, Wiggins, DM, Milin, RP, Hosendocus, SN. Risperidone effects in treatment-resistant adolescents: preliminary case reports. Journal of Child and Adolescent Psychopharmacology. 1995:5:6979.
97.Fisman, S, Steele, M, Short, J, Byrne, T, Lavallee, C. Case study: anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolesc Psychiatry. 1996:35:937940.
98.Demb, HB. Risperidone in young children with pervasive developmental disorders and other developmental disabilities. Journal of Child and Adolescent Psychopharmacology 1996:6:7980. Letter.
99.Fisman, S, Steele, M. Use of risperidone in pervasive developmental disorders: A case series. Journal of Child and Adolescent Psychopharmacology. 1996:6:177190.
100.Hardan, A, Johnson, K, Johnson, C, Hrecznyj, B. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry. 1996:35:15511556.
101.Lott, RS, Kerrick, JM, Cohen, SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull. 1994:32:721729.
102.McDougle, CJ, Holmes, JP, Bronson, MR, et al.Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997(36):685693.
103.Bymaster, FP, Calligaro, DO, Falcone, JF, et al.Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996; 14:8796.
104.Rubin, MLUse of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatric Annals. 1997:27:219221.
105.Megens, AAHP, Niemegeers, CJE, Awouters, FHL. Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol. J Pharmacol Exp Ther. 1992:260:160167.
106.Dixon, AK, Huber, C, Lowe, DA. Clozapine promotes approach-oriented behavior in male mice. J Clin Psychiatry. 1994;55(suppl B):47.
107.Prinssen, EPM, Ellenbroek, BA, Cools, AR. Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol. 1994:262:167170.
108.Corbett, R, Hartman, H, Kerman, LL, et al.Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav. 1993:45:917.
109.van der Linden, C, Bruggeman, R, van Woerkom, TCAM. Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone. Mov Disord. 1994:9:687688. Letter.
110.Swedo, SE, Leonard, HL. Trichotillomania: an obsessive compulsive spectrum disorder? Psychiatric Clin North Am. 1992:15:777790.
111.Swedo, SE, Leonard, HL, Rapoport, JL, Lenane, MC, Goldberger, EL, Cheslow, DL. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med. 1989:321:497501.
112.Stein, DJ, Hollander, E, Cohen, L, Simeon, D, Aronowitz, B. Serotonergic responsivity in trichotillomania: neuroendocrine effects of m-chlorophenylpiperazine. Biol Psychiatry. 1995:37:414416.
113.Ninan, FT, Rothbaum, BO, Stipetic, M, Lewine, RJ, Risch, SC. CSF 5-HIAA as a predictor of treatment response in trichotillomania. Psychopharmacol Bull. 1992:28:451455.
114.Rapoport, JL, Swedo, SE, Leonard, HL. Childhood obsessive-compulsive disorder. J Clin Psychiatry. 1992:53:1116.
115.Lindley, P, Marks, I, Philpott, R, Snowden, J. Treatment of obsessive-compulsive neurosis with history of childhood autism. Br J Psychiatry. 1977:130:592597.
116.McDougle, CJ, Goodman, WK, Price, LH. The pharmacotherapy of obsessive compulsive disorder. Pharmacopsychiatry. 1993;26(suppl):2429.
117.Foa, EB. Failures in treating obsessive-compulsives. Behav Res Ther. 1979:17:169176.
118.Insel, TR, Mueller, EA, Alterman, A, Linnoila, M, Murphy, DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985:20:11741188.
119.Kanner, L. Autistic disturbances of affective contact. Journal of Nervous Child. 1943:2:217250.
120.McDougle, CJ, Fleischmann, RL, Epperson, CN, Wasylink, S, Leckman, JF, Price, LH. Risperidone addition in fluvoxamine-refractory obsessive compulsive disorder: three cases. J Clin Psychiatry. 1995:56:526528.
121.Saxena, S, Wang, D, Bystritsky, A, Baxter, LR Jr., Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996:57:303306.
122.Stein, DJ, Bouwer, MB, Hawkridge, S, Emsley, RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry. 1997:58:119122.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 17 *
Loading metrics...

Abstract views

Total abstract views: 312 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 20th June 2018. This data will be updated every 24 hours.